A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Journal of Evolution of Medical and Dental Sciences
BACKGROUND Co-carbidopa was the first drug introduced for restless leg syndrome. But its use is not advocated much due to increased incidence of augmentation amongst the users. The first dopaminergic drug that was used in the treatment of RLS was co-carbidopa. However, it was noted in subsequent studies that there was a decline in the efficacy of co-carbidopa and there was an increase in the frequency, duration and intensity of symptoms with increased duration of co-carbidopa therapy which wasdoi:10.14260/jemds/2019/399 fatcat:zrfwyszykfg4naw57y3kkhhlou